Microglial depletion and activation: A [11C]PBR28 PET study in nonhuman primates
Hillmer AT, Holden D, Fowles K, Nabulsi N, West BL, Carson RE, Cosgrove KP. Microglial depletion and activation: A [11C]PBR28 PET study in nonhuman primates. EJNMMI Research 2017, 7: 59. PMID: 28741281, PMCID: PMC5524658, DOI: 10.1186/s13550-017-0305-0.Peer-Reviewed Original ResearchBrain microgliaTranslocator proteinAcute lipopolysaccharide administrationArterial blood samplingPositron emission tomography (PET) imagingReceptor kinase inhibitorMicroglia changesLipopolysaccharide administrationNeuroimmune functionMicroglial depletionMicroglia dynamicsTSPO levelsBlood samplingPET studiesOne animalKinase inhibitorsTomography imagingBaselineConclusionsThese studiesBrainMicrogliaImaging paradigmMacaca mulattaPreliminary evidenceImportant targetA multi species evaluation of the radiation dosimetry of [11C]erlotinib, the radiolabeled analog of a clinically utilized tyrosine kinase inhibitor
Petrulli JR, Hansen SB, Abourbeh G, Yaqub M, Bahce I, Holden D, Huang Y, Nabulsi NB, Contessa JN, Mishani E, Lammertsma AA, Morris ED. A multi species evaluation of the radiation dosimetry of [11C]erlotinib, the radiolabeled analog of a clinically utilized tyrosine kinase inhibitor. Nuclear Medicine And Biology 2017, 47: 56-61. PMID: 28126682, PMCID: PMC5360653, DOI: 10.1016/j.nucmedbio.2016.12.009.Peer-Reviewed Original ResearchConceptsTyrosine kinase inhibitorsTime-activity curvesEquivalent doseNon-small cell lung cancer patientsStage IIIA NSCLC patientsEpidermal growth factor receptor (EGFR) mutationsCell lung cancer patientsCritical organsKinase inhibitorsIIIA NSCLC patientsLung cancer patientsHighest equivalent doseTime-integrated activity coefficientsWhole bodyMean equivalent dosesRhesus macaque monkeysNSCLC patientsDosimetry profileCancer patientsGallbladder wallReceptor mutationsMacaque monkeysIdentifiable organsInjected activityEffective dose